Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

2.100 +0.020 (+0.96%) As of 03:48PM HKT. Market open.

Shanghai Bio-heart Biological Technology Co., Ltd.

Building 4
Room 302, 3rd Floor No.590 Ruiqing Road E. Zhangjiang Hi-Tech Park, Pudong New A
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 32

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Li Wang	Executive Chairman of the Board, CEO & GM	763.32k	N/A	1968
Mr. Yunqing Wang	CFO, Joint Company Secretary & Executive Director	1.26M	N/A	1985
Ms. Peili Wang	Financial Manager & Executive Director	813.99k	N/A	1984
Dr. Bradley Stewart Hubbard D.V.M., DVM	Chief Medical Officer	N/A	N/A	1959
Ms. Siu Ying Kwok	Joint Company Secretary	N/A	N/A	1985
Mr. Tao Cai	Chairperson of the Board of Supervisors & Head of Technology of BRS	174.66k	N/A	1987

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

Shanghai Bio-heart Biological Technology Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.